4.8 Review

Alzheimer's Disease Genetics: From the Bench to the Clinic

期刊

NEURON
卷 83, 期 1, 页码 11-26

出版社

CELL PRESS
DOI: 10.1016/j.neuron.2014.05.041

关键词

-

资金

  1. NIH [K01 AG046374, AG035083]
  2. Barnes Jewish Foundation
  3. Genentech
  4. Pfizer
  5. DIAN Pharma-Consortium (Biogen Idec)
  6. DIAN Pharma-Consortium (Eisai)
  7. DIAN Pharma-Consortium (Elan Pharmaceuticals)
  8. DIAN Pharma-Consortium (Eli Lilly and Company)
  9. DIAN Pharma-Consortium (FORUM Pharmaceuticals)
  10. DIAN Pharma-Consortium (Hoffman La-Roche)
  11. DIAN Pharma-Consortium (Genentech)
  12. DIAN Pharma-Consortium (Janssen Alzheimer Immunotherapy)
  13. DIAN Pharma-Consortium (Mithridion)
  14. DIAN Pharma-Consortium (Novartis Pharm AG)
  15. DIAN Pharma-Consortium (Pfizer Biotherapeutics Research Development)
  16. DIAN Pharma-Consortium (Sanofi-Aventis)
  17. Anonymous Foundation
  18. [AG044546]

向作者/读者索取更多资源

Alzheimer's disease (AD) is a clinically heterogeneous neurodegenerative disease with a strong genetic component. Several genes have been associated with AD risk for nearly 20 years. However, it was not until the recent technological advances that allow for the analysis of millions of polymorphisms in thousands of subjects that we have been able to advance our understanding of the genetic complexity of AD susceptibility. Genome-wide association studies and whole-exome and whole-genome sequencing have revealed more than 20 loci associated with AD risk. These studies have provided insights into the molecular pathways that are altered in AD pathogenesis, which have, in turn, provided insight into novel therapeutic targets.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据